c-mos immunoreactivity is an indicator of good prognosis in lung cancer.
Athanasiou A, Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Liloglou T, Karameris A, Foukas P, Manolis EN, Field JK, Kittas C.
Athanasiou A, et al. Among authors: manolis en.
Histopathology. 2000 Jul;37(1):45-54. doi: 10.1046/j.1365-2559.2000.00898.x.
Histopathology. 2000.
PMID: 10931218